BIOA ▲ +1.7% - BioAge Labs, Inc. $BIOA - BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema BioAge Labs rose 1.7% following its announcement that the first patient has been enrolled in QUELL-DME, a Phase 2 trial evaluating BGE-102, the company's oral NLRP3 inhibitor candidate, for diabetic macular edema. The dosing milestone represents progress in the clinical development of the company's lead asset for an inflammatory eye condition affecting diabetic patients. 08-SEP-2026 08:02 AM ET